Avalo Therapeutics (AVTX) EPS (Weighted Average and Diluted) (2015 - 2026)
Avalo Therapeutics (AVTX) reported EPS (Weighted Average and Diluted) of -$0.98 for Q1 2026, up 21.6% on a YoY basis from -$0.81 in Q1 2025, and down 164.86% quarter-over-quarter from -$0.37 in Q4 2025.
Avalo Therapeutics (AVTX) EPS (Weighted Average and Diluted) (2015 - 2026) Analysis & Trends
Avalo Therapeutics has reported EPS (Weighted Average and Diluted) for 11 years, with the latest figure at -$0.98 in Q1 2026.
- For the quarter ending Q1 2026, EPS (Weighted Average and Diluted) rose 21.6% year-over-year to -$0.98; the trailing twelve-month figure through Mar 2026 stood at -$5.46 (up 66.77% YoY), and the FY2025 full-year result was -$5.84, up 72.07% from the prior year.
- EPS (Weighted Average and Diluted) for Q1 2026 stood at -$0.98, down from -$0.37 in the prior quarter.
- The five-year high for EPS (Weighted Average and Diluted) was $117.47 in Q4 2023, with the low at -$1059.6 in Q4 2022.
- Historically, EPS (Weighted Average and Diluted) has averaged -$87.07 across 5 years, with a median of -$2.19 in 2025.
- The largest YoY upside for EPS (Weighted Average and Diluted) was 116.27% in 2022 against a maximum downside of 54802.07% in 2022.
- Avalo Therapeutics' EPS (Weighted Average and Diluted) stood at -$1059.6 in 2022, then soared by 111.09% to $117.47 in 2023, then sank by 98.54% to $1.72 in 2024, then plunged by 121.51% to -$0.37 in 2025, then plunged by 164.86% to -$0.98 in 2026.
- The last three EPS (Weighted Average and Diluted) figures came in at -$0.98 (Q1 2026), -$0.37 (Q4 2025), and -$2.19 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Weighted Avg. Diluted) (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | 0.68 |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 3.06 |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 3,086.42 |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | 0.00 |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | 0.00 |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 4.02 |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -0.61 |
| 10 | Avalo Therapeutics | 295.77 Mn | 295.77 Mn | - | -0.98 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -0.98 |
| Dec 31, 2025 | -0.37 |
| Sep 30, 2025 | -2.19 |
| Jun 30, 2025 | -1.92 |
| Mar 31, 2025 | -1.25 |
| Dec 31, 2024 | 1.72 |
| Sep 30, 2024 | -2.83 |
| Jun 30, 2024 | -14.07 |
| Mar 31, 2024 | -141.14 |
| Dec 31, 2023 | 117.47 |
| Sep 30, 2023 | -26.83 |
| Jun 30, 2023 | -140.73 |
| Mar 31, 2023 | -204.00 |
| Dec 31, 2022 | -1,059.61 |
| Sep 30, 2022 | 0.34 |
| Jun 30, 2022 | -1.38 |
| Mar 31, 2022 | -2.35 |
| Dec 31, 2021 | -1.93 |
| Sep 30, 2021 | -2.09 |
| Jun 30, 2021 | -2.12 |